These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 24839960

  • 1. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
    Omote Y, Deguchi K, Kono S, Liu W, Kurata T, Hishikawa N, Yamashita T, Ikeda Y, Abe K.
    J Neurosci Res; 2014 Oct; 92(10):1330-7. PubMed ID: 24839960
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
    Shinohara K, Hirooka Y, Ogawa K, Kishi T, Yasukawa K, Utsumi H, Sunagawa K.
    Clin Exp Hypertens; 2012 Oct; 34(6):456-62. PubMed ID: 22471901
    [Abstract] [Full Text] [Related]

  • 3. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
    Nagasu H, Satoh M, Yorimitsu D, Tomita N, Sasaki T, Kashihara N.
    Kidney Blood Press Res; 2011 Oct; 34(2):87-96. PubMed ID: 21273789
    [Abstract] [Full Text] [Related]

  • 4. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 5. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M.
    Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
    [Abstract] [Full Text] [Related]

  • 6. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
    Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M.
    J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
    [Abstract] [Full Text] [Related]

  • 7. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K, Ogihara T, Saruta T, Kuramoto K, REZALT Study Group.
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [Abstract] [Full Text] [Related]

  • 8. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

  • 9. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 10. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
    Guo Q, Minami N, Mori N, Nagasaka M, Ito O, Kurosawa H, Kanazawa M, Kohzuki M.
    Hypertens Res; 2008 Mar; 31(3):525-33. PubMed ID: 18497473
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K.
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 14. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H, Morishita T, Nakano A, Amaya N, Fukuoka Y, Ishida K, Arakawa K, Lee JD, Tada H.
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [Abstract] [Full Text] [Related]

  • 15. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
    Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y.
    Kidney Blood Press Res; 2009 May; 32(4):239-49. PubMed ID: 19752573
    [Abstract] [Full Text] [Related]

  • 16. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K.
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
    [Abstract] [Full Text] [Related]

  • 17. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K.
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [Abstract] [Full Text] [Related]

  • 18. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
    Ushigome E, Matsumoto S, Oyabu C, Ushigome H, Yokota I, Hasegawa G, Nakamura N, Tanaka M, Yamazaki M, Fukui M.
    J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 20. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
    Okamura K, Ito M, Tanaka K, Chinushi M, Adachi T, Mitsuma W, Hirono S, Nakazawa M, Kodama M, Aizawa Y.
    Pharmacology; 2009 Oct; 83(6):360-6. PubMed ID: 19440002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.